Award Amount: Up to $600,000 based on stage and scope of research, for one year Additional Information - If you are interested in applying, please reach out to Lynn Wong or Gwen Allouch with the Office of Advancement.
Alzheimer's Drug Discovery Foundation: Neuroimaging and CSF Biomarker Development Program
Application Due Date: Letter of Intent Due October 9, 2020
The aim of this RFP is to develop biomarkers for which there is a clear clinical need in Alzheimer's disease and related dementias.
Specifically, this RFP focuses on:
- Developing novel PET ligands for clinical use
- Supporting novel CSF biomarkers
- Validating established MRI approaches in larger cohorts
- Peripheral biofluids and digital approaches are supported through the Diagnostics Accelerator RFP.
Novel biomarkers of neuroinflammation and synaptic integrity are considered high-priority. Other target areas of interest include:
- Neuronal loss
- Vascular injury and blood-brain barrier integrity
- Mitochondria and metabolic function
- Protein misfolding/proteostasis
- Oxidative stress
- White matter changes
- Other novel targets supported by compelling biological rationale and connection to the disease
The Alzheimer's Drug Discovery Foundation has limited interest in CSF measures of amyloid and tau.